Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 12:3:60.
doi: 10.21037/tgh.2018.08.03. eCollection 2018.

Resection for intrahepatic cholangiocellular cancer: new advances

Affiliations
Review

Resection for intrahepatic cholangiocellular cancer: new advances

Daniel R Waisberg et al. Transl Gastroenterol Hepatol. .

Abstract

Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent primary liver neoplasm after hepatocellular carcinoma (HCC), corresponding to 10% to 15% of cases. Pathologies that cause chronic biliary inflammation and bile stasis are known predisposing factors for development of ICC. The incidence and cancer-related mortality of ICC is increasing worldwide. Most patients remain asymptomatic until advance stage, commonly presenting with a liver mass incidentally diagnosed. The only potentially curative treatment available for ICC is surgical resection. The prognosis is dismal for unresectable cases. The principle of the surgical approach is a margin negative hepatic resection with preservation of adequate liver remnant. Regional lymphadenectomy is recommended at time of hepatectomy due to the massive impact on outcomes caused by lymph node (LN) metastasis. Multicentric disease, tumor size, margin status and tumor differentiation are also important prognostic factors. Staging laparoscopy is warranted in high-risk patients to avoid unnecessary laparotomy. Exceedingly complex surgical procedures, such as major vascular, extrahepatic bile ducts and visceral resections, ex vivo hepatectomy and autotransplantation, should be implemented in properly selected patients to achieve negative margins. Neoadjuvant therapy may be used in initially unresectable lesions in order to downstage and allow resection. Despite optimal surgical management, recurrence is frustratingly high. Adjuvant chemotherapy with radiation associated with locoregional treatments should be considered in cases with unfavorable prognostic factors. Selected patients may undergo re-resection of tumor recurrence. Despite the historically poor outcomes of liver transplantation for ICC, highly selected patients with unresectable disease, especially those with adequate response to neoadjuvant therapy, may be offered transplant. In this article, we reviewed the current literature in order to highlight the most recent advances and recommendations for the surgical treatment of this aggressive malignancy.

Keywords: Cholangiocarcinoma; biliary tract cancer; intrahepatic; liver transplantation; resection; surgery.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Liver autotransplantation for cholangiocarcinoma. (A) Arterial phase of computed tomography scan showing large hypervascular lesion of 6.5 cm × 4.5 cm on hepatic veins confluence, infiltrating segments I, II, IV and VIII. (B) Coronal cut showing the invasion on right hepatic vein (red arrow). Anterior branch of the right portal vein (green arrow) is preserved. (C) Ex vivo left hepatectomy was performed, with partial removal of inferior vena cava and right hepatic vein. A deceased donor iliac vein graft was used for reconstruction on back table. (D) Final aspect of the reimplanted right lobe after venous reconstruction.

References

    1. Zhang XF, Bagante F, Chen Q, et al. Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. Surgery 2018;163:1114-20. 10.1016/j.surg.2018.01.001 - DOI - PubMed
    1. Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011;146:683-9. 10.1001/archsurg.2011.116 - DOI - PubMed
    1. Aljiffry M, Abdulelah A, Walsh M, et al. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature, J Am Coll Surg 2009;208:134-47. 10.1016/j.jamcollsurg.2008.09.007 - DOI - PubMed
    1. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472-7. 10.1016/j.jhep.2003.11.030 - DOI - PubMed
    1. Dodson RM, Weiss MJ, Cosgrove D, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 2013;217:736-50.e4. 10.1016/j.jamcollsurg.2013.05.021 - DOI - PubMed